secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELI LILLY & Co (LLY)
CIK:        0000059478
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0000059478-25-000202
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lilly Q2 revenue $15.56B (+38% YoY), EPS $6.29 (+92%), raises FY guidance
-------------------------------------------------------------------------

- Q2 revenue $15.56B, up 38% YoY, driven by volume growth from Zepbound and Mounjaro.
- Reported EPS $6.29, up 92%; non-GAAP EPS $6.31, up 61%, both inclusive of $0.14 IPR&D charges.
- Full-year revenue guidance raised $1.5B to $60-62B; reported EPS guided $20.85-22.10; non-GAAP EPS $21.75-23.00.
- Pipeline progress: positive results for orforglipron in obesity, Mounjaro SURPASS CVOT in T2D and heart disease, and Jaypirca vs Imbruvica in CLL/SLL.
- Completed acquisitions of SiteOne Therapeutics and Verve Therapeutics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/59478/000005947825000202/0000059478-25-000202-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/59478/000005947825000202/lly-20250807.htm
  HTML page:      https://secwatch.observer/filing/0000059478-25-000202

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer